TWI241302B - Lactam compounds and pharmaceutical use thereof - Google Patents

Lactam compounds and pharmaceutical use thereof Download PDF

Info

Publication number
TWI241302B
TWI241302B TW090129582A TW90129582A TWI241302B TW I241302 B TWI241302 B TW I241302B TW 090129582 A TW090129582 A TW 090129582A TW 90129582 A TW90129582 A TW 90129582A TW I241302 B TWI241302 B TW I241302B
Authority
TW
Taiwan
Prior art keywords
group
substituent
diabetic
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TW090129582A
Other languages
English (en)
Inventor
Yukio Iino
Takao Ikenoue
Nobuo Kondo
Hiroyuki Matsueda
Toshihiro Hatanaka
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of TWI241302B publication Critical patent/TWI241302B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)

Description

1241302 A8 B8 C8 D8 ___ 六、申請專利範園 1 Q ·如申請專利範圍第8項之內醯胺化合物或其製 藥學上容許之鹽,其中一般式(I )之3和1)之碳原子的 絕對配置皆爲s、C之碳原子之絕對配置爲R或S者。 1 1 · 一種輸糖增強作用劑,其特徵爲以下述一般式 (I )所示內醯胺化合物或其製藥學上容許之鹽爲有效成 分者,
〔上式中,A表示碳原子所構成單環或二環所成芳環 ’以碳’及選自氮、氧及硫之雜原子所構成5〜7員之1〜3 個環所成雜環,或碳原子所構成單環或二環所成脂環,R 2 、R3和R4可爲相同或不同,分別獨立示氫原子、鹵素原 子、羥基、碳數1〜18烷基、碳數1〜18烷氧基、碳數1〜12 院硫基、碳數1〜12院磺醯基、醯基、胺基、竣基、碳數1 〜8烷氧羰基、硝基、三氟甲基,可具有取代基之碳數1〜6 炔基,可具有取代基之以碳原子構成之碳數5〜12芳基’可 具有取代基之以碳及氮、氧、硫等構成之5〜7員之1〜3個 環所成雜芳基,可具有取代基之苯甲氧基’ B示可具有取 代基之以碳原子構成之單環或二個環所成之芳環’可具有 取代基之以碳及氮、氧、硫所等構成之5〜7員之1〜3個環 ---------------訂------Φ (請先閲·«背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) -5 - 1241302 Λ8 B8 C8 D8 _ 六、申請專利範圍 所成雜環,或可具有取代基以碳原子構成之單環或二個環 所成之脂環, (請先閱讀背面之注意事項再填寫本頁) —X —係一 NH —、一 NR5 — (R5係碳數1〜6之低 級火兀基)、—S —、— C Η 2 —, 一 Υ —係—ΝΗ —、一 NR5 — (R5係碳數1〜6之低 級烷基,可具有取代基之醯基,碳數1〜8之烷氧羰基,在 氮上可具有碳數1〜6之直鏈狀或岐鏈狀或環狀之烷基之胺 甲醯基,在硫原子上可具有碳數1〜6之直鏈狀或岐鏈狀或 環狀烷基之磺醯基)、一 0 —, —Z —可爲—NH —、— CH2 —、— CR6r7_ ( R6示氫原子、R7爲可具有取代基之碳數1〜18之烷基), —W —不—NRi —、或一CR8r9—(式中,Ri示氫原 子,可具有取代基之碳數丨〜6低級烷基,R 8、R 9示氫原 子),a、b、c分別示碳原子之位置, 但是, (i )上述取代基係選自鹵素原子、羥基、烷基、院 氧基、烷硫基、醯基、胺基、烷氧羰基、三氟甲基、芳基 所構成群〕。 經濟部智慧財產局員工消費合作社印製 1 2 ·如申請專利範圍第1 1項之輸糖增強作用劑, 其中一般式(I )中,A示芳環、雜環或脂環,R2、r3 和R4可爲相同或不同構造,分別獨立示氫原子、鹵素原子 、經基、院基、院氧基、院硫基、垸磺醯基、醯基、胺基 、羧基、院氧擬基、硝基、三氟甲基,可具有取代基之芳 基’可具有取代基之雜芳基,可具有取代基之苯甲氧基, 本紙張;d逋用中@國家標準(CNS ) ( 21GX297公釐) — 1241302 A8 B8 C8 D8 六、申請專利範圍 可具有取代基之芳環,可具有取代基之雜環,或可具 有取代基之脂環, ^ X -係—N Η -、— N R 5 — ( R 5係低級烷基)— S —、一 C Η 2 —, —γ〜係—ΝΗ —、— NR5— (R5係低級烷基,可具有 取代基之醯基、烷氧羰基、胺甲醯基、磺醯基)、-〇- —z —可爲—NH —、— CH2 —、— CR6R7 —(尺6係 氫原子、R7爲可具有取代基之碳數1〜18之烷基),一 w —示—NR1—或—CR8R9 —(式中,R1示氫原子,可 具有取代基之碳數1〜6低級烷基,R 8、R 9分別示氫原子 )° 1 3 · —種糖輸送增強作用劑,其特徵爲以如申請專 利範圍第1項〜第1 〇項中任一項之內醯胺化合物或其製 藥學上容許之鹽爲有效成分者。 1 4 · 一種降血糖劑,其特徵爲以如申請專利範圍第 1項〜第1 2項中任一項之內醯胺化合物或其製藥學上容 許之鹽爲有效成分者。 1 5 · —種糖尿病、糖尿病性末梢神經障礙、糖尿病 性腎症、糖尿病性網膜症、糖尿病性大血管症、耐糖能異 常症或肥胖症之預防和/或治療劑,其特徵爲以如申請專 利範圍第1項〜第1 2項中任一項之內醯胺化合物或其製 藥學上容許之鹽爲有效成分者。 本紙張尺度適用中國國家榇準(CNS ) A4規格(210X297公釐) ---------ΛΨ—I (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製
TW090129582A 2000-12-01 2001-11-29 Lactam compounds and pharmaceutical use thereof TWI241302B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01

Publications (1)

Publication Number Publication Date
TWI241302B true TWI241302B (en) 2005-10-11

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090129582A TWI241302B (en) 2000-12-01 2001-11-29 Lactam compounds and pharmaceutical use thereof

Country Status (26)

Country Link
US (3) US7153850B2 (zh)
EP (1) EP1346993B1 (zh)
JP (2) JP3826400B2 (zh)
KR (1) KR100826818B1 (zh)
CN (2) CN1269818C (zh)
AT (1) ATE446297T1 (zh)
AU (3) AU1850202A (zh)
BG (1) BG107857A (zh)
BR (1) BR0115852A (zh)
CA (1) CA2430124C (zh)
CZ (1) CZ20031520A3 (zh)
DE (1) DE60140270D1 (zh)
ES (1) ES2331299T3 (zh)
HU (1) HUP0400806A3 (zh)
IL (1) IL156158A0 (zh)
MX (1) MXPA03004876A (zh)
NO (1) NO325401B1 (zh)
NZ (1) NZ526164A (zh)
PL (1) PL362835A1 (zh)
RU (1) RU2287530C2 (zh)
SK (1) SK6582003A3 (zh)
TW (1) TWI241302B (zh)
UA (1) UA76969C2 (zh)
WO (1) WO2002044180A1 (zh)
YU (1) YU42603A (zh)
ZA (1) ZA200304100B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269818C (zh) * 2000-12-01 2006-08-16 味之素株式会社 内酰胺化合物及其药物用途
BRPI0407303A (pt) * 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica
CA2544310A1 (en) * 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
WO2005068467A1 (ja) 2004-01-14 2005-07-28 Ajinomoto Co., Inc. 新規縮環化合物
AU2006241684A1 (en) * 2005-04-28 2006-11-09 Ajinomoto Co., Inc. Novel lactam compound
WO2008126920A1 (ja) 2007-04-11 2008-10-23 Ajinomoto Co., Inc. 糖尿病治療薬
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
KR20170095850A (ko) * 2014-12-22 2017-08-23 이에이 파마 가부시키가이샤 각막 상피 장애 치료제
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
MX2021008937A (es) * 2019-01-23 2021-11-12 Glycolysis Biomed Co Ltd Compuestos de beta-lactama o sales de los mismos para su uso en la prevencion o tratamiento de accion prolongada del trastorno del metabolismo de la glucosa.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
PT1000059E (pt) 1997-07-30 2004-12-31 Wyeth Corp Agonistas triciclicos de vasopressina
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
CN1269818C (zh) 2000-12-01 2006-08-16 味之素株式会社 内酰胺化合物及其药物用途
BRPI0407303A (pt) * 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica

Also Published As

Publication number Publication date
CA2430124C (en) 2011-01-11
CA2430124A1 (en) 2002-06-06
AU2006241377B2 (en) 2009-01-08
NZ526164A (en) 2004-09-24
CN1269818C (zh) 2006-08-16
UA76969C2 (en) 2006-10-16
YU42603A (sh) 2006-03-03
NO325401B1 (no) 2008-04-21
US7632830B2 (en) 2009-12-15
BG107857A (bg) 2004-06-30
NO20032439L (no) 2003-07-18
CN1487940A (zh) 2004-04-07
ATE446297T1 (de) 2009-11-15
KR100826818B1 (ko) 2008-05-02
KR20030051893A (ko) 2003-06-25
US7326701B2 (en) 2008-02-05
JP3826400B2 (ja) 2006-09-27
HUP0400806A2 (hu) 2004-07-28
SK6582003A3 (en) 2003-09-11
US20060189597A1 (en) 2006-08-24
BR0115852A (pt) 2003-12-23
EP1346993A4 (en) 2005-12-21
CZ20031520A3 (cs) 2003-10-15
HUP0400806A3 (en) 2007-11-28
DE60140270D1 (de) 2009-12-03
CN100577651C (zh) 2010-01-06
MXPA03004876A (es) 2004-01-27
ZA200304100B (en) 2004-08-22
RU2287530C2 (ru) 2006-11-20
ES2331299T3 (es) 2009-12-29
JP2006213732A (ja) 2006-08-17
NO20032439D0 (no) 2003-05-28
US7153850B2 (en) 2006-12-26
US20080096862A1 (en) 2008-04-24
AU2006241377A1 (en) 2006-12-14
AU1850202A (en) 2002-06-11
CN1911915A (zh) 2007-02-14
US20040048847A1 (en) 2004-03-11
JPWO2002044180A1 (ja) 2004-04-02
AU2002218502B2 (en) 2006-09-21
WO2002044180A1 (fr) 2002-06-06
EP1346993B1 (en) 2009-10-21
IL156158A0 (en) 2003-12-23
EP1346993A1 (en) 2003-09-24
PL362835A1 (en) 2004-11-02
JP4505753B2 (ja) 2010-07-21

Similar Documents

Publication Publication Date Title
TWI241302B (en) Lactam compounds and pharmaceutical use thereof
CA2516370C (en) A process of preparing imatinib and imatinib prepared thereby
CA2958095C (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
Adams et al. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity
AU2005335298C1 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP3819024B2 (ja) 置換ピリミジン化合物およびその使用
CA2613303A1 (en) An oxime derivative for use as a glucokinase activator
CA2771775A1 (en) Compounds and compositions as protein kinase inhibitors
CA2474104A1 (en) N-oxides of n-phenyl-2-pyrimidine-amine derivatives
ATE303387T1 (de) Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
MX2010006182A (es) Derivados de isoxazolo-piridazina.
RS20080191A (en) Pyrazole derivatives and their medical use
AR035722A1 (es) Derivados de indol, procesos para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la produccion de medicamentos
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
MY143578A (en) Piperazinediones as oxytocin receptor antagonists
UA70966C2 (uk) Піримідини, що інгібують реплікацію віл
RS65704A (en) Aza-arylpiperazines
CA2412941A1 (en) Piperidine compounds for use as ccr-3 inhibitors
JP2006213732A5 (zh)
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
IL291590B1 (en) Novel modified quinoline-8-carbonitrile compounds with androgen receptor unblocking activity and their uses
CA2635093A1 (en) Derivatives of sulindac, use thereof and preparation thereof
CA2462903A1 (en) Beta-lactamyl vasopressin v1a antagonists
CA2438524A1 (en) Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
CA2531484A1 (en) Novel bioisosteres of actinonin

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees